As we all know, President Trump has returned to the White House after a three-day stay at Walter Reed National Military Medical Center, where he was hospitalized with COVID-19. His care is continuing around the clock in the White House Medical Unit by a team of healthcare providers led by Dr. Sean Conley, the personal physician to the President.
There continues to be a cloud of misinformation and a cloak of secrecy regarding his condition, along with questions about why he received such aggressive treatment in the hospital. President Trump is at risk for severe COVID. He’s over 65, he’s obese, and he may have other risk factors of which the public is not aware. It’s concerning to hear that he required supplemental oxygen at least twice over the weekend. His lowest oxygen levels were reported to be 93 or 94 percent. Since oxygen therapy is not routinely given for those levels, evidence-based medicine would suggest that his oxygen levels may have been lower than that.
Although the President got surprisingly aggressive medical treatment in the hospital, he appears not to have received either of the two therapeutics he has been touting publicly: hydroxychloroquine or convalescent plasma. According to news reports, in addition to taking a slew of non-prescription medications, including Vitamin D, zinc, melatonin, aspirin, and the heartburn medication Pepcid, the President was an early recipient of a series of treatments that have only been shown to improve the prognosis in patients who are severely ill with COVID.
He is on dexamethasone, a high-dose steroid. A published drug trial of more than 6,400 patients with COVID who were either receiving continuous oxygen or using a mechanical ventilator showed that a 10-day course of dexamethasone reduced 28-day mortality. But President Trump met neither of those criteria.
The President is also on remdesivir, an antiviral medication. Supplies of this drug are limited, and there’s insufficient data to recommend either for or against its use in patients with mild or moderate COVID-19. He also received a dose of an experimental antibody cocktail made by Regeneron that is designed to boost a patient’s immune system. Keep in mind: this medication has only been delivered to 275 trial patients. As I said, it’s experimental, and it has not received emergency use approval from the Food and Drug Administration (FDA). There’s no data to support the use of either of these treatments, based on the President’s reported condition.
An ethical rule in modern medicine is “first do no harm.” Did President Trump’s doctors ignore that part of the Hippocratic Oath? If these medications were truly indicated, the President was much sicker than his doctors reported. If they were not indicated, then the President is a victim of what some doctors refer to as “VIP syndrome.” VIP syndrome occurs when special treatments are given to famous or well-connected people, regardless of need or documented efficacy.
You and I can’t get the three medications that President Trump got, and that may be a good thing. One reason: the President may be the first person ever to receive all three of those treatments. The possible consequences of this combination are unknown. Another reason: studies show there is no proven benefit, and there’s the possibility of harm, in patients who received dexamethasone, but did not require continuous oxygen. Yet another reason is that high-dose dexamethasone can cause short-term, steroid-induced psychosis and other psychiatric side effects, especially in the elderly.
Just because President Trump has been discharged does not mean that he has recovered from COVID. Physicians taking care of COVID patients use the term “falling off the cliff” to describe a sudden change in acute oxygenation that can occur within the first 7-10 days of this illness. In addition to any potential side effects from the aggressive use of the medications he was given, the President is still at risk for acute worsening in his condition.
Whether he was actually sicker than reported, or he was subjected to overly aggressive “VIP” care, or determined his own time of discharge because he is the President, the next week will be critical in determining President Trump’s medical course and prognosis.
Hotly anticipated performance targets and payment amounts for the Centers for Medicare & Medicaid Services (CMS) Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) Model
I often begin my day with an environmental scan. Last week, an article from Becker’s Clinical Leadership caught my eye, “Hospital mortality, infectionrates improve despite
Please log in to your account to comment on this article.
Sepsis sequencing continues to challenge even experienced coding and CDI professionals, with evolving guidelines, documentation gaps, and payer scrutiny driving denials and data inconsistencies. In this webcast, Payal Sinha, MBA, RHIA, CCDS, CDIP, CCS, CCS-P, CCDS-O, CRC, CRCR, provides clear guideline-based strategies to accurately code sepsis, severe sepsis, and septic shock, assign POA indicators, clarify the relationship between infection and organ dysfunction, and align documentation across teams. Attendees will gain practical tools to strengthen audit defensibility, improve first-pass accuracy, support appeal success, reduce denials, and ensure accurate quality reporting, empowering organizations to achieve consistent, compliant sepsis coding outcomes.
Expert presenters Kathy Pride, RHIT, CPC, CCS-P, CPMA, and Brandi Russell, RHIA, CCS, COC, CPMA, break down complex fracture care coding rules, walk through correct modifier application (-25, -57, 54, 55), and clarify sequencing for initial and subsequent encounters. Attendees will gain the practical knowledge needed to submit clean claims, ensure compliance, and stay one step ahead of payer audits in 2026.
Accurately determining the principal diagnosis is critical for compliant billing, appropriate reimbursement, and valid quality reporting — yet it remains one of the most subjective and error-prone areas in inpatient coding. In this expert-led session, Cheryl Ericson, RN, MS, CCDS, CDIP, demystifies the complexities of principal diagnosis assignment, bridging the gap between coding rules and clinical reality. Learn how to strengthen your organization’s coding accuracy, reduce denials, and ensure your documentation supports true medical necessity.
Denials continue to delay reimbursement, increase administrative burden, and threaten financial stability across healthcare organizations. This essential webcast tackles the root causes—rising payer scrutiny, fragmented workflows, inconsistent documentation, and underused analytics—and offers proven, data-driven strategies to prevent and overturn denials. Attendees will gain practical tools to strengthen documentation and coding accuracy, engage clinicians effectively, and leverage predictive analytics and AI to identify risks before they impact revenue. Through real-world case examples and actionable guidance, this session empowers coding, CDI, and revenue cycle professionals to shift from reactive appeals to proactive denial prevention and revenue protection.
Federal auditors are intensifying their focus on inpatient psychiatric facilities, using advanced data analytics to spotlight outliers and pursue high‑dollar repayments. In this high‑impact webcast, Michael Calahan, PA, MBA, Compliance Officer and V.P., Hospital & Physician Compliance, breaks down what regulators are really targeting in IPF-PPS admissions, documentation, treatment and discharge planning. Attendees will learn practical steps to tighten processes, avoid common audit triggers and protect reimbursement and reduce the risk of multimillion-dollar repayment demands.
In this timely session, Stacey Shillito, CDIP, CPMA, CCS, CCS-P, CPEDC, COPC, breaks down the complexities of Medical Decision Making (MDM) documentation so providers can confidently capture the true complexity of their care. Attendees will learn practical, efficient strategies to ensure documentation aligns with current E/M guidelines, supports accurate coding, and reduces audit risk, all without adding to charting time.
Join Ronald Hirsch, MD, FACP, CHCQM for The PEPPER Returns – Risk and Opportunity at Your Fingertips, a practical webcast that demystifies the PEPPER and shows you how to turn complex claims data into actionable insights. Dr. Hirsch will explain how to interpret key measures, identify compliance risks, uncover missed revenue opportunities, and understand new updates in the PEPPER, all to help your organization stay ahead of audits and use this powerful data proactively.
Stay ahead of the 2026-2027 audit surge with “Top 10 Audit Targets for 2026-2027 for Hospitals & Physicians: Protect Your Revenue,” a high-impact webcast led by Michael Calahan, PA, MBA. This concise session gives hospitals and physicians clear insight into the most likely federal audit targets, such as E/M services, split/shared and critical care, observation and admissions, device credits, and Two-Midnight Rule changes, and shows how to tighten documentation, coding, and internal processes to reduce denials, recoupments, and penalties. Attendees walk away with practical best practices to protect revenue, strengthen compliance, and better prepare their teams for inevitable audits.
Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more
Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 1 with code CYBER25
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
